Clinical application of 20 MHz endosonography and anti-Helicobacter pylori immunoblots to predict regression of low-grade gastric MALtoma by H. pylori eradication

Bor Shyang Sheu, Shu Chu Shiesh, Jin Town Wang, Hsiao Bai Yang, Shih Ting Lin, Jiunn Jong Wu

研究成果: Article

11 引文 (Scopus)

摘要

Aim. We tested whether serial 20 MHz endosonography (EUS) and anti-Helicobacter pylori immunoblots can predict the complete regression of gastric MALToma by H. pylori eradication. Methods. The serums of 17 MALToma patients, including 15 with low grade and two with high grade, were collected before therapy. Fifteen patients with low-grade MALToma and 18 nonMALToma patients, all infected with H. pylori, have been followed with serum sampling, endoscopy, and EUS on enrollment, on the 2nd, 6th, and 12th months after anti-H. pylori therapy. All sera were tested for anti-H. pylori immunoblots, including 19.5, 26.5, 30, 35, 89, 116 KDa (CagA), FldA. The DNAs were extracted serially from the biopsy of MALToma patients before and after therapy to perform polymerase chain reaction (PCR) for the immunoglobulin heavy-chain gene monoclonality. Results. MALToma patients had higher prevalence rates of anti-FldA protein, 19.5 and 30 KDa antibodies of H. pylori (p < 0.01). After H. pylori eradication, MALToma patients had negative seroconversion of 19.5, 26.5, 30, and 35 KDa antibodies (p < 0.05), but not in CagA and FldA. The PCR monoclonality occurred in 80% (12/15) of the MALToma patients before therapy, but did not correlate with any seroconversion of anti-H. pylori immunoblots after therapy (p > 0.05). Complete regression of MALToma was observed in 73.3% (11/15) of patients. Evaluation with 20 MHz EUS, for the initial tumor depth and its normalization on the 6th month had 90.9% sensitivity and 100% specificity to predict the complete regression. Discussion. The negative seroconversions of the smaller-molecular-weight proteins, but not CagA and FldA, correlate with regression of MALToma by H. pylori eradication. 20 MHz EUS can effectively predict the therapeutic response of MALToma.

原文English
頁(從 - 到)36-45
頁數10
期刊Helicobacter
8
發行號1
DOIs
出版狀態Published - 2003 四月 12

指紋

Endosonography
Helicobacter pylori
Stomach
Serum
Immunoglobulin Heavy Chain Genes
Therapeutics
Endoscopy
Proteins
Molecular Weight
Biopsy
Sensitivity and Specificity
Polymerase Chain Reaction
Antibodies
DNA

All Science Journal Classification (ASJC) codes

  • Gastroenterology
  • Infectious Diseases

引用此文

@article{cdac1b1d78db4d04bf882365559c907b,
title = "Clinical application of 20 MHz endosonography and anti-Helicobacter pylori immunoblots to predict regression of low-grade gastric MALtoma by H. pylori eradication",
abstract = "Aim. We tested whether serial 20 MHz endosonography (EUS) and anti-Helicobacter pylori immunoblots can predict the complete regression of gastric MALToma by H. pylori eradication. Methods. The serums of 17 MALToma patients, including 15 with low grade and two with high grade, were collected before therapy. Fifteen patients with low-grade MALToma and 18 nonMALToma patients, all infected with H. pylori, have been followed with serum sampling, endoscopy, and EUS on enrollment, on the 2nd, 6th, and 12th months after anti-H. pylori therapy. All sera were tested for anti-H. pylori immunoblots, including 19.5, 26.5, 30, 35, 89, 116 KDa (CagA), FldA. The DNAs were extracted serially from the biopsy of MALToma patients before and after therapy to perform polymerase chain reaction (PCR) for the immunoglobulin heavy-chain gene monoclonality. Results. MALToma patients had higher prevalence rates of anti-FldA protein, 19.5 and 30 KDa antibodies of H. pylori (p < 0.01). After H. pylori eradication, MALToma patients had negative seroconversion of 19.5, 26.5, 30, and 35 KDa antibodies (p < 0.05), but not in CagA and FldA. The PCR monoclonality occurred in 80{\%} (12/15) of the MALToma patients before therapy, but did not correlate with any seroconversion of anti-H. pylori immunoblots after therapy (p > 0.05). Complete regression of MALToma was observed in 73.3{\%} (11/15) of patients. Evaluation with 20 MHz EUS, for the initial tumor depth and its normalization on the 6th month had 90.9{\%} sensitivity and 100{\%} specificity to predict the complete regression. Discussion. The negative seroconversions of the smaller-molecular-weight proteins, but not CagA and FldA, correlate with regression of MALToma by H. pylori eradication. 20 MHz EUS can effectively predict the therapeutic response of MALToma.",
author = "Sheu, {Bor Shyang} and Shiesh, {Shu Chu} and Wang, {Jin Town} and Yang, {Hsiao Bai} and Lin, {Shih Ting} and Wu, {Jiunn Jong}",
year = "2003",
month = "4",
day = "12",
doi = "10.1046/j.1523-5378.2003.00122.x",
language = "English",
volume = "8",
pages = "36--45",
journal = "Helicobacter",
issn = "1083-4389",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Clinical application of 20 MHz endosonography and anti-Helicobacter pylori immunoblots to predict regression of low-grade gastric MALtoma by H. pylori eradication

AU - Sheu, Bor Shyang

AU - Shiesh, Shu Chu

AU - Wang, Jin Town

AU - Yang, Hsiao Bai

AU - Lin, Shih Ting

AU - Wu, Jiunn Jong

PY - 2003/4/12

Y1 - 2003/4/12

N2 - Aim. We tested whether serial 20 MHz endosonography (EUS) and anti-Helicobacter pylori immunoblots can predict the complete regression of gastric MALToma by H. pylori eradication. Methods. The serums of 17 MALToma patients, including 15 with low grade and two with high grade, were collected before therapy. Fifteen patients with low-grade MALToma and 18 nonMALToma patients, all infected with H. pylori, have been followed with serum sampling, endoscopy, and EUS on enrollment, on the 2nd, 6th, and 12th months after anti-H. pylori therapy. All sera were tested for anti-H. pylori immunoblots, including 19.5, 26.5, 30, 35, 89, 116 KDa (CagA), FldA. The DNAs were extracted serially from the biopsy of MALToma patients before and after therapy to perform polymerase chain reaction (PCR) for the immunoglobulin heavy-chain gene monoclonality. Results. MALToma patients had higher prevalence rates of anti-FldA protein, 19.5 and 30 KDa antibodies of H. pylori (p < 0.01). After H. pylori eradication, MALToma patients had negative seroconversion of 19.5, 26.5, 30, and 35 KDa antibodies (p < 0.05), but not in CagA and FldA. The PCR monoclonality occurred in 80% (12/15) of the MALToma patients before therapy, but did not correlate with any seroconversion of anti-H. pylori immunoblots after therapy (p > 0.05). Complete regression of MALToma was observed in 73.3% (11/15) of patients. Evaluation with 20 MHz EUS, for the initial tumor depth and its normalization on the 6th month had 90.9% sensitivity and 100% specificity to predict the complete regression. Discussion. The negative seroconversions of the smaller-molecular-weight proteins, but not CagA and FldA, correlate with regression of MALToma by H. pylori eradication. 20 MHz EUS can effectively predict the therapeutic response of MALToma.

AB - Aim. We tested whether serial 20 MHz endosonography (EUS) and anti-Helicobacter pylori immunoblots can predict the complete regression of gastric MALToma by H. pylori eradication. Methods. The serums of 17 MALToma patients, including 15 with low grade and two with high grade, were collected before therapy. Fifteen patients with low-grade MALToma and 18 nonMALToma patients, all infected with H. pylori, have been followed with serum sampling, endoscopy, and EUS on enrollment, on the 2nd, 6th, and 12th months after anti-H. pylori therapy. All sera were tested for anti-H. pylori immunoblots, including 19.5, 26.5, 30, 35, 89, 116 KDa (CagA), FldA. The DNAs were extracted serially from the biopsy of MALToma patients before and after therapy to perform polymerase chain reaction (PCR) for the immunoglobulin heavy-chain gene monoclonality. Results. MALToma patients had higher prevalence rates of anti-FldA protein, 19.5 and 30 KDa antibodies of H. pylori (p < 0.01). After H. pylori eradication, MALToma patients had negative seroconversion of 19.5, 26.5, 30, and 35 KDa antibodies (p < 0.05), but not in CagA and FldA. The PCR monoclonality occurred in 80% (12/15) of the MALToma patients before therapy, but did not correlate with any seroconversion of anti-H. pylori immunoblots after therapy (p > 0.05). Complete regression of MALToma was observed in 73.3% (11/15) of patients. Evaluation with 20 MHz EUS, for the initial tumor depth and its normalization on the 6th month had 90.9% sensitivity and 100% specificity to predict the complete regression. Discussion. The negative seroconversions of the smaller-molecular-weight proteins, but not CagA and FldA, correlate with regression of MALToma by H. pylori eradication. 20 MHz EUS can effectively predict the therapeutic response of MALToma.

UR - http://www.scopus.com/inward/record.url?scp=0037237167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037237167&partnerID=8YFLogxK

U2 - 10.1046/j.1523-5378.2003.00122.x

DO - 10.1046/j.1523-5378.2003.00122.x

M3 - Article

C2 - 12603615

AN - SCOPUS:0037237167

VL - 8

SP - 36

EP - 45

JO - Helicobacter

JF - Helicobacter

SN - 1083-4389

IS - 1

ER -